Interventional Management of Intermediate-High-Risk Pulmonary Embolism: Current Evidence, Patient Selection and Personalised Treatment Strategies
Journal of Clinical Medicine · 28.06.2026 · 15 (13) · 5041
DOI: 10.3390/jcm15135041 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 28.06.2026. Verfasst von Patrycja Paszenda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland. Die Arbeit nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Intermediate-high-risk (IHR) pulmonary embolism (PE) remains one of the most challenging clinical phenotypes in contemporary PE management. Although haemodynamically stable at presentation, these patients remain at significant risk of clinical deterioration, right ventricular failure, and haemodynamic decompensation. Current management primarily relies on anticoagulation and close surveillance, while routine reperfusion therapy remains controversial due to the balance between potential haemodynamic benefit and bleeding risk. Catheter-based reperfusion strategies, including catheter-directed thrombolysis and mechanical thrombectomy, have emerged as potential alternatives to systemic thrombolysis in selected patients. However, despite growing procedural adoption, important uncertainties remain regarding optimal patient selection, timing of intervention, and comparative effectiveness. Current evidence demonstrates consistent short-term improvements in surrogate haemodynamic parameters, but robust evidence for reductions in mortality, recurrent PE, chronic thromboembolic complications, or long-term functional impairment remains limited. This narrative review critically evaluates contemporary catheter-based reperfusion strategies in IHR PE, focusing on methodological limitations of the current evidence base and unresolved challenges in clinical decision-making. It highlights the limitations of existing risk stratification models and the heterogeneity of IHR PE, where static risk categories often fail to capture dynamic clinical deterioration. Future progress in this field will likely depend on improved patient selection, refined risk assessment, and personalised reperfusion strategies supported by high-quality comparative trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.
- Student Scientific Organisation, Institute of Heart Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland.
- Institute of Heart Diseases, Jan Mikulicz Radecki University Hospital in Wroclaw, Borowska 213, 50-556 Wroclaw, Poland.
ORCID-Profile: Patrycja Paszenda, Agnieszka Kowalik, Robert Zymliński
Zitieren
APA
Paszenda, P., Kowalik, A., Profaska, I., Mroczek, E., Garus, M., Zymliński, R., Kuliczkowski, W., & Gajewski, P. (2026). Interventional Management of Intermediate-High-Risk Pulmonary Embolism: Current Evidence, Patient Selection and Personalised Treatment Strategies. Journal of Clinical Medicine, 15(13), 5041. https://doi.org/10.3390/jcm15135041
Vancouver
Paszenda P, Kowalik A, Profaska I, Mroczek E, Garus M, Zymliński R, et al. Interventional Management of Intermediate-High-Risk Pulmonary Embolism: Current Evidence, Patient Selection and Personalised Treatment Strategies. Journal of Clinical Medicine. 2026;15(13):5041. doi:10.3390/jcm15135041
BibTeX
@article{Paszenda2026,
author = {Paszenda, Patrycja and Kowalik, Agnieszka and Profaska, Izabella and Mroczek, Ewa and Garus, Mateusz and Zymliński, Robert and Kuliczkowski, Wiktor and Gajewski, Piotr},
title = {Interventional Management of Intermediate-High-Risk Pulmonary Embolism: Current Evidence, Patient Selection and Personalised Treatment Strategies},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {13},
pages = {5041},
doi = {10.3390/jcm15135041}
}
EUVIMED